Published in Antimicrob Agents Chemother on February 01, 2005
Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev (2005) 5.77
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Cell wall assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2006) 3.08
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 2.63
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet (2009) 2.15
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
How I treat mucormycosis. Blood (2011) 1.51
Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother (2008) 1.43
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol (2010) 1.27
Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One (2010) 1.25
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2009) 1.19
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Zygomycosis in Immunocompromised non-Haematological Patients. Mediterr J Hematol Infect Dis (2011) 1.13
Carbohydrate-active enzymes from the zygomycete fungus Rhizopus oryzae: a highly specialized approach to carbohydrate degradation depicted at genome level. BMC Genomics (2011) 1.10
CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest (2013) 1.04
Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother (2014) 1.01
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother (2007) 0.98
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother (2009) 0.98
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother (2009) 0.94
Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother (2006) 0.94
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother (2006) 0.93
Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother (2011) 0.93
Rapid detection and identification of mucormycetes from culture and tissue samples by use of high-resolution melt analysis. J Clin Microbiol (2010) 0.92
Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother (2013) 0.91
Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother (2010) 0.88
Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother (2014) 0.86
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother (2014) 0.84
Human fungal pathogens of mucorales and entomophthorales. Cold Spring Harb Perspect Med (2014) 0.82
Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother (2011) 0.81
Rapid detection and identification of mucormycetes in bronchoalveolar lavage samples from immunocompromised patients with pulmonary infiltrates by use of high-resolution melt analysis. J Clin Microbiol (2014) 0.80
Biology, systematics, and clinical manifestations of Zygomycota infections. Eur J Clin Microbiol Infect Dis (2014) 0.80
Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc (2010) 0.79
Breakthrough filamentous fungal infections in pediatric hematopoetic stem cell transplant and oncology patients receiving caspofungin. Can J Infect Dis Med Microbiol (2012) 0.79
Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. PLoS Pathog (2015) 0.79
Drug combinations against Mucor irregularis in vitro. Antimicrob Agents Chemother (2013) 0.78
Rhizomucor and scedosporium infection post hematopoietic stem-cell transplant. Case Rep Med (2011) 0.78
Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient: A Case Report. Medicine (Baltimore) (2017) 0.75
Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J (2015) 0.75
VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. Antimicrob Agents Chemother (2015) 0.75
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Ecancermedicalscience (2013) 0.75
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrob Agents Chemother (2017) 0.75
A Potential Explanation of a Positive Serum β-Glucan Assay in Mucormycosis. Open Forum Infect Dis (2016) 0.75
Zygomycetes in human disease. Clin Microbiol Rev (2000) 9.80
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis (1998) 2.96
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 2.73
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother (2002) 2.60
Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother (1987) 2.59
An Aspergillus fumigatus alkaline protease mutant constructed by gene disruption is deficient in extracellular elastase activity. Mol Microbiol (1992) 2.59
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol (1994) 2.33
Fungal beta(1,3)-D-glucan synthesis. Med Mycol (2001) 2.30
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother (2004) 2.28
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother (2002) 2.15
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother (2003) 2.01
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66
Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest (1984) 1.63
Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis (1997) 1.59
Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob Agents Chemother (2001) 1.55
Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother (1988) 1.55
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother (2004) 1.48
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action. J Antimicrob Chemother (1997) 1.37
Rhinocerebral invasive mycosis: occurrence in immunocompetent individuals. Eur J Radiol (1995) 1.16
Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia (1982) 1.14
Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother (2003) 1.11
Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother (2000) 1.10
Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother (2002) 1.07
Utility of mould susceptibility testing. Curr Opin Infect Dis (2003) 0.88
Problems of antifungal in vitro testing in Aspergillus fumigatus. Contrib Microbiol (1999) 0.86
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med (2005) 8.39
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog (2006) 3.58
Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol (2007) 3.43
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med (2008) 3.36
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol (2007) 3.02
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem (2004) 2.77
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 2.63
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis (2005) 2.42
Current treatment strategies for disseminated candidiasis. Clin Infect Dis (2005) 2.25
Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2004) 2.23
Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis (2007) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother (2003) 2.01
Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother (2006) 1.99
Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis (2010) 1.96
the hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog (2008) 1.94
Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother (2005) 1.90
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med (2012) 1.81
Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun (2003) 1.78
The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun (2008) 1.77
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 1.77
Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis (2011) 1.72
Dr. William H. Stewart: mistaken or maligned? Clin Infect Dis (2008) 1.71
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis (2006) 1.64
Seven ways to preserve the miracle of antibiotics. Clin Infect Dis (2013) 1.63
Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat (2003) 1.62
Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect Immun (2004) 1.59
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun (2005) 1.53
Functional analysis of the Candida albicans ALS1 gene product. Yeast (2004) 1.50
Global cell surface conformational shift mediated by a Candida albicans adhesin. Infect Immun (2004) 1.46
Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother (2008) 1.43
Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun (2005) 1.42
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother (2006) 1.40
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis (2008) 1.38
N-cadherin mediates endocytosis of Candida albicans by endothelial cells. J Biol Chem (2005) 1.36
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun (2005) 1.35
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest (2010) 1.34
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One (2012) 1.32
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol (2010) 1.27
Candida albicans Als proteins mediate aggregation with bacteria and yeasts. Med Mycol (2007) 1.26
A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol (2005) 1.23
The FDA reboot of antibiotic development. Antimicrob Agents Chemother (2013) 1.22
Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol (2006) 1.21
A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc Natl Acad Sci U S A (2002) 1.18
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett (2005) 1.18
To treat or not to treat: adjunctive antibiotics for uncomplicated abscesses. Ann Emerg Med (2011) 1.17
Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis (2010) 1.16
Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis (2008) 1.15
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov (2012) 1.13
Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett (2004) 1.11
Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol (2006) 1.11
Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother (2009) 1.10
The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun (2006) 1.10
Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother (2005) 1.09
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother (2009) 1.08
End points in trials of treatments for skin infections. JAMA (2013) 1.07
The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun (2013) 1.06
How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis (2012) 1.05
Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol (2009) 1.05
CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest (2013) 1.04
Antibacterial resistance leadership group: open for business. Clin Infect Dis (2014) 1.04
Community-acquired pneumonia. N Engl J Med (2014) 1.02
Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother (2014) 1.01
Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine (2012) 1.01
Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis (2002) 1.00
Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One (2013) 0.99
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Cdc42p GTPase regulates the budded-to-hyphal-form transition and expression of hypha-specific transcripts in Candida albicans. Eukaryot Cell (2004) 0.98
Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother (2012) 0.98
Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans. Eukaryot Cell (2008) 0.97
Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis (2010) 0.96